JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on February 5, 2004; DOI: 10.1124/jpet.103.063388


0022-3565/04/3093-1160-1166$20.00
JPET 309:1160-1166, 2004
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.103.063388v1
309/3/1160    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bos, R.
Right arrow Articles by Lechat, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bos, R.
Right arrow Articles by Lechat, P.

CARDIOVASCULAR

Potassium Canrenoate, an Aldosterone Receptor Antagonist, Reduces Isoprenaline-Induced Cardiac Fibrosis in the Rat

Romain Bos, Nathalie Mougenot, Odile Médiani, Paul M. Vanhoutte, and Philippe Lechat

Service de Pharmacologie, CHU Pitié Salpêtrière, Paris, France (R.B., N.M., O.M., P.L.); Institut Fédératif de Recherche 14 Coeur Muscles Vaisseaux, CHU Pitié-Salpêtrière, Paris, France (N.M., P.L.); and Department of Pharmacology, University of Hong Kong, Hong Kong, People's Republic of China (P.M.V.)

The purpose of the present study was to determine whether the administration of an antagonist of aldosterone could prevent the fibrosis induced by an acute injection of isoprenaline. Male Wistar rats were submitted to one subcutaneous injection of isoprenaline (400 mg/kg) and were simultaneously treated with potassium canrenoate in drinking water (20 mg/kg/day) started 5 days before the injection of isoprenaline. Two months later, echocardiographic and hemodynamic measurements were performed. Then, the heart was prepared for morphometric histology and quantification of fibrosis in the left ventricle. Heart and left ventricular weights were increased significantly by isoprenaline. Potassium canrenoate attenuated this increase. The administration of isoprenaline increased significantly end diastolic diameter and end systolic volume compared with control. These changes were increased further with the addition of potassium canrenoate. In contrast, the fibrosis induced by isoprenaline was reduced significantly by potassium canrenoate at the three section levels. Potassium canrenoate attenuated the fibrosis but not the enhanced dilatation of the left ventricle induced by isoprenaline.


Received November 28, 2003; accepted February 4, 2004.

Address correspondence to: Dr. Philippe Lechat, Service de Pharmacologie, Hôpital Pitié Salpêtrière, 47 boulevard de l'Hôpital, 75651 Paris cedex 13, France. E-mail: philippe.lechat{at}psl.ap-hop-paris.fr




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
M. Rahman, A. Nishiyama, P. Guo, Y. Nagai, G.-X. Zhang, Y. Fujisawa, Y.-Y. Fan, S. Kimura, N. Hosomi, K. Omori, et al.
Effects of Adrenomedullin on Cardiac Oxidative Stress and Collagen Accumulation in Aldosterone-Dependent Malignant Hypertensive Rats
J. Pharmacol. Exp. Ther., September 1, 2006; 318(3): 1323 - 1329.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics.